Annovis Bio Secures $6 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies

Annovis Bio Inc. has successfully closed a $6 million registered direct offering, marking a significant financial milestone for the clinical-stage biotechnology company focused on neurodegenerative disorders. The company sold 4 million shares of common stock at $1.50 per share, with H.C. Wainwright & Co. serving as the exclusive placement agent for the transaction. This capital infusion represents a critical step forward for Annovis Bio's development pipeline targeting Alzheimer's disease and Parkinson's disease, two conditions affecting millions of patients worldwide with limited treatment options currently available.

The gross proceeds of approximately $6 million, before deducting placement agent fees and other offering expenses, are designated for working capital and general corporate purposes. This funding comes at a pivotal time for the company as it advances its late-stage clinical programs. The financial backing will support ongoing research and development efforts, clinical trial operations, and the broader corporate infrastructure needed to bring potential therapies to market. Investors and stakeholders can access detailed information about the company's progress through its dedicated newsroom at https://ibn.fm/ANVS.

Annovis Bio's approach to neurodegenerative diseases represents an important area of medical research given the growing prevalence of conditions like Alzheimer's and Parkinson's as global populations age. The company's platform focuses on developing innovative treatments that could potentially slow or reverse the progression of these debilitating conditions. The successful completion of this offering demonstrates continued investor confidence in the company's scientific approach and development strategy despite the challenging financial environment for biotechnology companies.

The registered direct offering structure provides Annovis Bio with immediate capital while minimizing market disruption, allowing the company to maintain focus on its clinical objectives. This financial reinforcement enables the company to continue its important work in addressing one of healthcare's most pressing challenges. The full details of this financial transaction and the company's ongoing developments are available in the official press release accessible at https://ibn.fm/p55Nb. This funding round positions Annovis Bio to accelerate its mission of developing transformative treatments for patients suffering from neurodegenerative diseases who currently have limited therapeutic options.